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1. Introduction
Autism spectrum disorder (ASD) is a prevalent, life-long, neurodevelopmental disorder
diagnosed in more than 1% of children in the United States (the most recent estimate exceeds
one in 68 children) with strong gender basis towards males (one in 42 boys) relative to females
(one in 189 girls) [1]. In addition to the diagnostic impairments specified in the fifth edition of
the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for ASD in
socialization, restricted, repetitive patterns of behavior, interests, or activities, and communi‐
cation, which must be present in the early developmental period, many individuals diagnosed
with an ASD frequently have co-morbid aggression and severe irritability, hyperactivity, and
repetitive behaviors, which can become a major source of additional distress and can interfere
with functioning [2]. Similarly, others have observed the occurrence of co-morbid conditions
among individuals diagnosed with an ASD as follows: hyperactivity (67%), sensory processing
problems (85%), anxiety/fear (74%), behavioral problems (89%), and obsessive-compulsive
behaviors (92%) [3]. These investigators described that behavioral problems and obsessive-
compulsive behaviors were reported to be the most serious and problematic. In addition,
investigators described that some individuals diagnosed with an ASD show significant
deterioration in symptoms about the time of puberty [4]. Among the symptoms that worsened
according to these investigators were disruptive behavior, destructiveness, restlessness, and
partial loss of acquired social and academic skills.
In considering the aforementioned facts, it was previously hypothesized that male hormones
(androgens) may play a critically important role in the clinical presentation of individuals
diagnosed with an ASD and that reduction of androgens in individuals diagnosed with an
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ASD would result in a significant amelioration of their clinical symptoms [5]. The purpose of
this critical review is to examine evidence supporting the role of androgens in mediating ASD
traits/symptoms, elevated androgens among individuals diagnosed with an ASD, and the
observed important role for anti-androgen medications in treatment of ASD traits/symptoms.
2. Evidence for a correlation between elevated androgens and ASD traits/
symptoms
Investigators have systematically evaluated measurements of androgens and their relation‐
ship with the clinical symptoms or traits defining or observed in individuals diagnosed with
an ASD [6, 7]. Fetal testosterone levels were observed to be significantly inversely related to
eye contact, quality of social relationships, vocabulary size, and empathy among typically
developing children. By contrast, fetal testosterone levels were observed to significantly
positively correlate with autistic traits, restricted interests, and systemizing behaviors.
It was also determined on a psychological testing basis that were significant differences among
individuals diagnosed with an ASD in comparison to neurotypical males and females [6, 7].
The tests revealed that autism quotient (AQ), systemizing quotient (SQ), child autism spectrum
test (CAST), embedded figures test, intuitive physics test, social responsiveness scale, quanti‐
tative checklist for autism in toddlers (Q-CHAT) scores revealed a pattern of ASDs > males >
females. By contrast, empathy quotient (EQ), faux pas test, friendship and relationship
questionnaire (FQ), reading the mind in the eyes, and social stories questionnaire (SSQ) scores
revealed a pattern of females > males > ASDs.
Other investigators examined brain structure for evidence of an extreme male brain among
individuals diagnosed with an ASD in comparison to neurotypical males and females [6, 7].
A pattern of extreme male brain structure with ASD > males > females for total brain volume
and amgydala size was observed. By contrast, it was observed that the brain size was females
> males > ASD for the perisylvian language areas, left > right asymmetry in planum temporale,
and lateral fronto-parietal cortex. Furthermore, brain function patterns revealed females >
males > ASD for default mode network connectivity, embedded figures functional magnetic
resonance imaging (fMRI), and reading the mind in the eyes task fMRI.
Still other investigators examined the relationship between various diseases known to be
associated with elevated androgen levels and ASD traits and symptoms [6, 7]. For example,
individuals diagnosed with congenital adrenal hyperplasia (CAH) were found to have
increased problem behaviors and increases in AQ scores relative to unaffected controls. It was
even observed that some individuals diagnosed with DNA-confirmed CAH mutations and
associated clinical and laboratory findings had a concurrent diagnosis of an ASD. As another
example, individuals diagnosed with polycystic ovarian syndrome (PCOS) were observed to
have significantly increased AQ scores, significantly impaired communication, socialization,
and attention relative to unaffected controls. Finally, investigators examined bio-physiological
and cognitive differences in children diagnosed with premature adrenarche (with elevated
blood androgen levels) in comparison to on-time adrenarche [8]. Children diagnosed with
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premature adrenarche in comparison to on-time adrenarche had significantly increased
problem behaviors and attention problems, as well as significantly decreased skills in social‐
ization, information processing, language/communication.
Other investigators have more specifically examined the direct relationship between hormonal
treatment status and ASD traits/symptoms by examining various groups of transsexual
individuals [9] and among individuals injected with testosterone in a double-blind study [10].
It was observed among various groups of transsexual individuals that compared ASD traits/
symptoms using AQ scores derived from five groups: (1) n = 61 transmen (female-to-male
transsexual individuals); (2) n = 198 transwomen (male-to-female transsexual individuals); (3)
n = 76 typical males; (4) n = 98 typical females; and (5) n = 125 individuals diagnosed with an
ASD [9]. Higher AQ scores were seen in transmen than in typical females, typical males, or
trans women, but transmen had lower SQ scores than those individuals diagnosed with an
ASD. Transmen displayed ASD-like symptoms/traits and were more comfortable socializing
with male peers than female peers. Thus androgen treatment in transmen correlated directly
with development of ASD symptoms/traits. Transmen had a higher mean AQ than typical
females, typical males and transwomen, but lower than individuals diagnosed with an ASD.
Transmen have more ASD traits/symptoms and may have had difficulty socializing with
female peers and thus found it easier to identify with male peer groups. The importance of
these findings being that direct hormonal treatment with androgen therapy in transmen
directly correlated with their development of ASD traits/symptoms. It was also observed,
among individuals injected with testosterone in a double-blind study, that these individuals
manifested a significant increase in ASD traits/symptoms with impairment in their cognitive
ability to infer emotions, intentions, feelings, and other mental states from observing the eye
region of another's face [10].
3. Evidence for the effect of elevated androgens in ASD
Investigators have undertaken extensive evaluation of various measurements of elevated
androgens in individuals diagnosed with an ASD. They described, among individuals
diagnosed with an ASD, significantly increased frequency of genetic changes in multiple genes
involved in sex steroid synthesis, transport, and/or metabolism, testosterone-related medical
conditions (e.g., polycystic ovarian syndrome, breast and ovarian cancers, acne, etc.), and
testosterone-related characteristics (e.g., tomboyism, etc.)[6, 7]. It was also reported that
individuals diagnosed with an ASD had significant alterations in the timing of puberty (boys
diagnosed with an ASD were observed to enter "male" puberty earlier, while girls diagnosed
with an ASD were observed to enter "female" puberty later). Elevated androgen levels and
significantly lower second to fourth digit ratios in comparison to neurotypical controls (a
known marker of elevated fetal testosterone) [6, 7].
Investigators recently measured fetal steroidogenic activity in amniotic fluid samples for
individuals diagnosed with an ASD in comparison to neuroptypical controls. Amniotic fluid
samples taken from individuals subsequently diagnosed with an ASD in comparison to
neurotypical controls revealed significant elevations in androgen levels [11].
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Investigators previously described evaluating blood androgen levels among a large cohort of
individuals diagnosed with an ASD using routine laboratory testing from the Laboratory
Corporation of American (LabCorp) [12]. It was observed that individuals diagnosed with an
ASD were observed to have significant increases in their blood levels of testosterone, free
testosterone, dehydroepiandrosterone (DHEA), and androsternedione relative to laboratory
provided reference ranges. Overall, it was observed among the various blood androgen
attributes examined, that over 80% of the individuals diagnosed with an ASD examined were
found to have at least one of the blood androgen attributes examined that exceeded the age-
and sex-specific reference ranges provided by the laboratory.
Subsequently, other investigators evaluated the potential role of androgens among individuals
diagnosed with an ASD in comparison to neurotypical controls by examining salivary levels
of hormones among children from 3-4 years-old and 7-9 years-old [13]. These investigators
observed significantly higher salivary concentrations of androgens among individuals
diagnosed with an ASD relative to controls, and the anomalies were prominent in older male
children diagnosed with an ASD. Among the specific types of androgens observed to be
increased among individuals diagnosed with an ASD in comparison to neurotypical controls
were androstenediol, DHEA, and androsterone, which, the investigators concluded were
indicative of precocious andrenarche and predictive of early puberty. These investigators also
commented that some of the androgens observed were significantly increased among the
individuals diagnosed with an ASD relative to the neurotypical controls are known to
neuroactive and modulate GABA, glutamate, and opioid neurotransmission with the potential
consequence of affecting brain development and function. They may also contribute to ASD-
associated pathobiology and symptoms such as elevated anxiety, sleep disturbances, sensory
deficit, and stereotypic behaviors.
Similarly, other investigators examined hyperandrogenemia in male children and adolescents
diagnosed with an ASD in comparison to neuroptyical controls and in relation to ASD severity
by assessing serum androgen levels [14]. These investigators observed that androgen levels
were significantly higher among individuals diagnosed with an ASD in comparison to
neurotypical controls, and the elevations were observed to significantly correlate with ASD
severity. Overall, it was observed among individuals diagnosed with an ASD that 36.66% had
high serum free testosterone, 30% had high DHEA, 40% had high androstenedione, and 26.66%
showed elevation of all androgen levels in comparison to neurotypical controls. These
investigators concluded that hyperandrogenemia is prevalent among individuals diagnosed
with an ASD, correlate with ASD severity, and studies should explore the use of anti-androgen
therapy to treat such patients.
4. Treatment with anti-androgen medications in ASD
It was original hypothesized that given the significant correlation between androgen levels
and ASD symptoms/traits that administration of anti-androgen medications to individuals
diagnosed with an ASD would result in significant clinical improvements [5]. More recently
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other investigators extended this previous hypothesis by suggesting that circulating hormone
levels and the administration of testosterone and other hormones were found to predict
behavior in individuals, but the effect was suggested to be one of "activation" or "fine-tuning"
earlier organization of the brain [15].
Among the most-well studied anti-androgen medications are gonadotropin-releasing hor‐
mone (GnRH) analogues. GnRH analogues are synthetic peptide drugs modeled after human
hypothalamic GnRH, and are designed to interact with the GnRH receptor and modify the
release of pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hor‐
mone (LH) for therapeutic purposes, and over a period of time will lower the release of FSH
and LH from the pituitary leading to reversible suppression of androgen release [16].
The use of GnRH analogues in various animal model systems has been observed to signifi‐
cantly improve many ASD symptoms/traits, and the improvements observed were compara‐
ble to those for commonly used psychiatric medications for these conditions [7]. For example,
investigators studied the effects of GnRH agonists and antagonists on anxiety and social
behaviors in rats [17]. These investigators observed GnRH agonists significantly reduced
anxiety and increased social behaviors in the rats, and the overall effects were comparable to
those observed with diazepam. Other investigators examined the effects of GnRH agonists on
obsessive compulsive behaviors in mice. In one study it was observed that a GnRH agonist
was able to significantly reduce marble-burying behaviors, a model system for obsessive-
compulsive behaviors, comparable to that observed with fluoxeteine administration [18], and
in another it was observed that a GnRH agonist was able to significantly reduce marble-
burying behaviors comparable to that observed with ritanserin administration [19]. Finally,
investigators observed that GnRH agonist therapy significantly improved hyperactivity
behaviors in mice [20].
In addition to studies of animal model systems demonstrating the improvement of ASD
symptoms/traits by GnRH analogues, a number of investigators have observed similar
phenomena in human populations. For example, investigators examined the acute gonadal
suppression effects of GnRH antagonists on sexual and behaviors in a case-series of men [21].
It was observed the treatment resulted in significant reduction in outward-direct aggression
in all of the treated men with some also experiencing reductions in anxiety and sexual desire.
Other investigators reported on the use of a GnRH analogue to treat obsessive-compulsive
disorder in a clinical trial [22]. During the course of the 48 week clinical trial, it was observed
that GnRH analogue therapy was effective in significantly reducing the severity of the
symptoms of obsessive-compulsive disorder. Another investigator described the use of a
GnRH analgoue as a means to treat problems behaviors in men suffering from dementia [23].
It was observed that within 4 weeks of the start of therapy, verbal and physical aggression had
decreased; activity disturbances such as agitation, pacing, and restlessness were markedly
reduced; and a significant reduction in disruptive sexual behaviors was observed.
Investigators have reported on the successful use of GnRH analogues in the treatment of sexual
problem behaviors/symptoms in individuals diagnosed with an ASD over several decades.
For example, investigators described that administration of an GnRH analogue to an individ‐
ual diagnosed with an ASD and sexual behavior resulted in significant suppression of the
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patient's sexual behaviors [24]. Similarly, other investigators described the use of GnRH
analogues in the treatment of individuals diagnosed with an ASD and central precocious
puberty [25]. These investigators described that many individuals diagnosed with an ASD
tend to have early sexual maturation, and they described a case-series of patients with
precocious puberty ranging from 6 years and 9 months-old to 9 years and 6 months-old.
Treatment with a GnRH analogue to help alleviate their symptoms of precocious puberty,
especially given that these symptoms were not well-tolerated in the context of the individual's
ASD diagnoses. These investigators concluded that treatment of sexual precocity should be
considered among individuals diagnosed with an ASD not only based upon their bone age
maturation and growth, but also their mental maturation.
Finally, investigators described the successful use of the GnRH analogue, leuprolide acetate,
in the treatment of ASD traits/symptoms in a clinical trial of consecutive individuals diagnosed
with an ASD with laboratory findings showing elevated androgen levels [26]. Each patient
was clinically studied at base line and at the end of the study, to evaluate hyperandrogenemia
behavior/symptoms including secondary sexual changes, facial and body hair, early growth
spurt and aggressive behaviors. A clinical examination was undertaken for each individual to
evaluate clinical symptoms/behaviors of hyperandrogenemia such as early growth spurt, early
secondary sexual changes, body and facial hair, and aggressive behaviors at baseline and at
the end of the study period for each child. Autism Treatment Evaluation Checklist (ATEC)
evaluations were completed by the child's parents prior to beginning the protocol and at the
end of the study period for each child. The children received 15 mg of leuprolide acetate depot
by intramuscular injection every 28 days. This dose was supplemented with a daily subcuta‐
neous injection of leuprolide acetate so that each child received a total initial starting doses of
50 ug of leuprolide acetate/kilogram of body weight-daily. The children were monitored, and
increased subcutaneous doses of leuprolide acetate or oral anti-androgen medication were
administered to those children who exhibited persistent laboratory/clinical signs of elevated
androgen as clinically indicated. The participants were enrolled in the study for a minimum
of 2 months and a maximum of 7 months. Each child underwent laboratory testing at baseline
and again after approximately 3 of treatment. Treated children were observed to significantly
improve from a median baseline score of 87 (70th percentile of autism severity) to a median
score of 63 (40-49th percentile of autism severity) by the completion of the study. Significant
improvements among treated children when evaluating baseline measurements in compari‐
son to those obtained at the end of the study period, were observed in the specific areas of
sociability, cognitive awareness, and behavior. Additionally, trial participants having inde‐
pendent assessments by school evaluators showed significant improvements in general school
skills mastered and significant improvements in the frequency and severity of disruptive/
oppositional behavior at the end of the treatment period relative to baseline, despite the fact
that the evaluators were unaware of the child's participation in the trial.
Comparison of clinical evaluation at baseline with evaluation at the trials conclusion showed
significant reductions in hyperandrogenemia evidenced in clinical symptoms and the associ‐
ated behaviors (early secondary sexual changes, early growth spurt, body and facial hair, and
aggressive behaviors). A significant decrease in serum testosterone levels was demonstrated
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by laboratory testing, and the treatment protocol did not significant adversely affect kidney,
thyroid or liver function tests.
Since their study employed therapeutic agents designed to lower androgen levels, and
significant decreases in androgen levels were observed, the researchers concluded the
treatment protocol studied presented a novel method to significantly reduce autistic-like
behaviors. Further, the study reported that significant autistic behavior improvements (i.e.,
improvements in hyperactivity and attention, better sleep patterns, and increased socializa‐
tion) occurred within days of the treatment with leuprolide acetate. Finally, the study con‐
cluded that leuprolide acetate significantly ameliorated clinical behaviors/systems of
hyperandrogenemia including aggressive behaviors,, early secondary sexual changes,, body
and facial hair, and early growth spurt among children diagnosed with an ASD.
Other investigators reported that the administration of leuprolide acetate therapy to nearly
200 individuals diagnosed with an ASD [12] resulted in significantly lowered androgen levels
very significant overall clinical improvements in sensory/cognitive awareness, socialization,
and health/physical/behavior skills. Leuprolide acetate treatment resulted in significant
clinical ameliorations in aggression, self injury, abnormal sexual behaviors, hyperactivity/
impulsivity, stereotypy, and/or irritability behaviors in many individuals diagnosed with an
ASD. Minimal adverse clinical effects to the therapy were seen, and there were with few non-
responders.
Children were administered an intramuscular injection of 15 mg leuprolide acetate depot every
28 days and supplemented with daily, subcutaneously injected leuprolide acetate, so that
children were started on a dose of 50 μg of leuprolide acetate/kilogram bodyweight/day.
Children were monitored as successive doses of leuprolide acetate were administered for
persistent clinical/laboratory signs of increased androgens, and subjects were treated with
additional subcutaneous injections of leuprolide acetate dosing and/or an oral anti-androgen
medicine as clinically necessary.
Children examined in the study were on the therapy for a minimum of 2 months and a
maximum of 7 months. Laboratory testing was conducted on each child at baseline and at
approximately 3 months of treatment. Among the children treated in the clinical trial, there
was a significant overall improvement from the 70th percentile of severity (median baseline
score = 87) at baseline to the 40-49th percentile of severity (median end of study period score
= 63) at the end of the study. In the specific areas of sociability, cognitive awareness, and
behavior, there were significant improvements among treated children when evaluating
baseline measurements in comparison to those obtained at the end of the study period.
Additionally, for specific subjects participating in the clinical trial having independent
assessments by school evaluators, who were not aware of the treatment status of the child,
there were significant improvements in general school skills mastered and significant im‐
provements in the frequency and severity of disruptive/oppositional behavior at the end of
the treatment period relative to baseline.
When comparing the clinical examinations undertaken for each child at baseline and at the
end of the study period, significant reductions in clinical symptoms and the associated
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behaviors of hyperandrogenemia (such as early growth spurt, early secondary sexual changes,
body and facial hair, and aggressive behaviors) were noted. Laboratory testing revealed a
significant decrease in serum testosterone levels. It was observed that the treatment protocol
did not significant adversely affect kidney, thyroid or liver function tests.
As a result, the investigators concluded, since their study employed therapeutic agents that
were designed to lower androgen levels, and significant decreases in androgen levels were
observed, the treatment protocol presented a novel method for helping to significantly reduce
autistic-like behaviors. Furthermore, the investigators reported that in some of the children
examined, significant autistic behavior improvements (i.e., better sleep patterns, improve‐
ments in attention and hyperactivity, and increased socialization) occurred within days of the
administration of leurpolide acetate. Finally, the investigators concluded that leuprolide
acetate administration significantly helped to ameliorate clinical symptoms/behaviors of
hyperandrogenemia such as early growth spurt, early secondary sexual changes, body and
facial hair, and aggressive behaviors that may be observed among some children diagnosed
with an ASD.
Subsequently, other investigators described their clinical experience following the adminis‐
tration of leuprolide acetate therapy to nearly 200 individuals diagnosed with an ASD [10].
Leuprolide  acetate  administration  significantly  lowered androgen levels  and resulted  in
very  significant  overall  clinical  improvements  in  socialization,  sensory/cognitive  aware‐
ness,  and health/physical/behavior skills,  with few non-responders and minimal adverse
clinical  effects  to  the  therapy.  Leuprolide  acetate  administration also  resulted in  signifi‐
cant  quantitative  clinical  ameliorations  in  hyperactivity/impulsivity,  stereotypy,  aggres‐
sion,  self  injury,  abnormal  sexual  behaviors,  and/or  irritability  behaviors  in  many
individuals diagnosed with an ASD.
Recently, investigators have purposed clinical guidelines for the evaluation and treatment of
androgen dysfunction in individuals diagnosed with an ASD[7, 27]. It is important when
considering medicines such as leuprolide acetate for the treatment of individuals diagnosed
with an ASD, to consider that such therapy is not intended to deprive the individual of their
sexuality nor alter their normal developmental trajectory. Instead, the initiation of such
therapy is designed to regularize a process that was proceeding in an abnormal fashion and
producing adverse effects. Thus, the use of anti-androgen medicines, such as leuprolide
acetate, can safely improve the health of the individual diagnosed with an ASD by reducing
in the frequency and intensity of their ASD traits/symptoms
In considering the in-use safety of GnRH analogues in the treatment of individuals diagnosed
with an ASD, they have been on the market for many years, and many individuals have
received GnRH analogues for many years to treat conditions such as prostate cancer, female
reproductive problems, and premature puberty without serious adverse effects [7]. Studies of
individuals receiving GnRH-analogue therapy for many years in the treatment of premature
puberty reported that GnRH analogue administration was not associated with long-term
reproductive dysfunction. The patients had normal menarche normal ovarian function etc. No
impaired physical development was observed. The patients had normal body composition,
normal body mass index, normal bone mineral density, etc. No reduction in the secretion of
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sex hormones in men and women was observed [7]. In 2009 the American Academy of
Pediatrics issued a consensus statement describing that GnRH analogues are generally well
tolerated in adolescents and children. Systemic complaints such as hot flashes or headaches
occur occasionally but are usually short-term and do not interfere with therapy [28].
In previous long-term follow-up of individuals receiving GnRH-analogue therapy in the
treatment of premature puberty for many years, the studies reported that GnRH analogue
administration was not associated with long-term reproductive dysfunction (normal ovarian
function, normal menarche, etc.); impaired physical development (normal body mass index,
normal body composition, normal bone mineral density, etc.); or reduced secretion of sex
hormones in women and men [7]. The American Academy of Pediatrics in 2009 issued a
consensus statement describing that GnRH analogues are generally well tolerated in children
and adolescents, and systemic complaints such as headaches or hot flashes occur occasionally
but are usually short-term and do not interfere with therapy [28].
Furthermore, when considering the safety profile of GnRH analogues among individuals
diagnosed with an ASD, it is important to evaluate them in the context of currently used
psychotropic medicines. For example, risperidone is currently approved by the US Food and
Drug Administration (FDA) for the treatment of individuals diagnosed with an ASD. Inves‐
tigators recently reported on the long-term treatment effects of risperidone on prolactin levels,
sexual side-effects, and bone mineral density in pubertal boys diagnosed with an ASD [29-31].
The individuals diagnosed an ASD examined were physically healthy 10 to 20 year-old males
chronically treated with risperidone for an average of 52 months (range 16 to 126 months). It
was observed when comparing individuals chronically treated with risperidone in comparison
to individuals not treated with any antipsychotic medicine, hyperprolactinemia was present
in 47% of the chronically treated individuals in comparison to only 2% of the individuals not
treated with any antipsychotic medicine. In addition, gynecomastia and sexual dysfunction
were present in 43% and 14% of the individuals chronically treated with risperidone in
comparison to 21% and 0% of individuals not treated with any antipsychotic medicine.
Individuals chronically treated with antipsychotic medicines who developed hyperprolacti‐
nemia were compared to individuals not treated with any antipsychotic medicine and had no
hyperprolactinemia. The patients treated with antipsychotic medicines had significantly lower
lumbar spine bone mineral density scores, higher percentage of body fat, and a lower bio‐
chemical bone marker carboxyterminal cross-linking telopeptide of bone collagen. Finally, it
was observed among individuals chronically treated with antipsychotic medicines who
developed hyperprolactinemia in comparison to individuals not treated with any antipsy‐
chotic medicine who did not have hyperprolactinemia had significantly lower testosterone
levels.
5. Conclusion
The present critical review provides evidence for hyperandrogenism as a significant feature
among ASD. Further, many studies have shown a significant correlation between the traits/
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symptoms  of  individuals  diagnosed  with  an  ASD  and  hyperandrogenism.  Finally,  the
present  critical  review  presents  data  from  animal  models  and  human  clinical  trials
demonstrating  that  medication  with  anti-androgens  significantly  improve  certain  traits/
symptoms exhibited by individuals diagnosed with an ASD.
The present critical review provides evidence for hyperandrogenism as a significant feature
among individuals diagnosed with an ASD. Further, many investigations have revealed a
significant correlation between the traits/symptoms of individuals diagnosed with an ASD
and hyperandrogenism. Finally, the present critical review presents data from animal models
and human clinical trials demonstrating that anti-androgen medications have the ability to
significantly improve certain traits/symptoms exhibited by individuals diagnosed with an
ASD.
In light of the high prevalence of individuals diagnosed with an ASD and the paucity of safe
and effective medical treatments to help these individuals, anti-androgen therapy should be
considered as it is an effective and relatively safe means to significantly help improve the
adverse traits/symptoms exhibited by individuals diagnosed with an ASD. By directly
targeting a traits/symptoms and/or biomedical indicators when elevated beyond the normal
ranges, this therapy controls difficult traits/symptoms associated with high androgens such
as self injurious behaviors and aggression, and, thus, contributes to the quality of the individ‐
ual's life and the normalcy of the individual's home life.
It is recommended that all individuals diagnosed with an ASD should be screened for elevated
androgens and elevated androgen-associated traits/symptoms as part of a standard initial
clinical assessment. In addition, these same type of blood and clinical traits/symptoms should
be assessed within the affected individual's family, so as to produce not only treatment options
for the individual diagnosed with an ASD but also an understanding of why these conditions
occur and who may be at risk. Finally, for those appropriate individuals diagnosed with an
ASD, anti-androgen treatment should be offered.
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